Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chitosan for mucosal vaccination.

I M van der Lubben1, J C Verhoef, G Borchard

  • 1Leiden/Amsterdam Center for Drug Research, Division of Pharmaceutical Technology, P.O. Box 9502, 2300 RA Leiden, The Netherlands.

Advanced Drug Delivery Reviews
|November 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Considerations for the delivery of STING ligands in cancer immunotherapy.

Journal of controlled release : official journal of the Controlled Release Society·2021
Same author

Encapsulation of VEGF<sub>165</sub> into magnetic PLGA nanocapsules for potential local delivery and bioactivity in human brain endothelial cells.

Journal of materials chemistry. B·2020
Same author

Equivalence of glatiramer acetate products: challenges in assessing pharmaceutical equivalence and critical clinical performance attributes.

Expert opinion on drug delivery·2017
Same author

[Carbapenemase producing Enterobacteriaceae in the Netherlands: unnoticed spread to several regions].

Nederlands tijdschrift voor geneeskunde·2017
Same author

Association of chitosan and aluminium as a new adjuvant strategy for improved vaccination.

International journal of pharmaceutics·2017
Same author

Peptide-decorated chitosan derivatives enhance fibroblast adhesion and proliferation in wound healing.

Carbohydrate polymers·2016
Same journal

Silicone oil in protein drug products and its implications for formulation stability.

Advanced drug delivery reviews·2026
Same journal

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD).

Advanced drug delivery reviews·2026
Same journal

Lysosome-targeting degrader delivery system: from formulation design to biomedical applications.

Advanced drug delivery reviews·2026
Same journal

Anti-PEG antibodies in nanomedicine: Mechanisms, risks, and opportunities.

Advanced drug delivery reviews·2026
Same journal

Optimizing macrophage-targeted intracellular delivery systems for safe and effective immunotherapies.

Advanced drug delivery reviews·2026
Same journal

Light-controlled CRISPR-dCas9 epigenome editing: advanced drug-delivery strategies and oncology applications.

Advanced drug delivery reviews·2026
See all related articles

Chitosan particles show promise for mucosal vaccines, enhancing immune responses when delivered orally or nasally. This approach improves vaccine uptake and efficacy at pathogen entry sites.

Area of Science:

  • Biomaterials Science
  • Immunology
  • Vaccinology

Background:

  • Mucosal vaccination offers advantages by generating local antibodies at pathogen entry points.
  • Conventional mucosal vaccines require enhancers or carriers for sufficient uptake.
  • Chitosan is a versatile biopolymer capable of forming micro- and nanoparticles.

Purpose of the Study:

  • To evaluate chitosan-based delivery systems for mucosal vaccination.
  • To assess the efficacy of chitosan micro/nanoparticles in enhancing mucosal and systemic immunity.

Main Methods:

  • Encapsulation of model antigens (ovalbumin, diphtheria toxoid, tetanus toxoid) within chitosan particles.
  • Administration of chitosan-antigen formulations via oral and nasal routes in vaccination studies.

Related Experiment Videos

  • Assessment of particle uptake by gut-associated lymphoid tissue (GALT), specifically Peyer's patches.
  • Evaluation of mucosal and systemic immune responses post-vaccination.

    • Main Results:

    • Chitosan effectively forms microparticles and nanoparticles encapsulating antigens.
    • Ovalbumin-loaded chitosan microparticles demonstrated uptake by Peyer's patches.
    • Co-administration of chitosan with antigens via nasal route significantly enhanced mucosal and systemic immune responses.
    • Chitosan particulate systems show potential for oral vaccine delivery due to Peyer's patch uptake.

    Conclusions:

    • Chitosan particles, powders, and solutions are effective carriers for mucosal vaccine delivery.
    • Chitosan enhances both mucosal and systemic immunity, making it suitable for oral and nasal vaccination.
    • Mucosal vaccination with chitosan offers cost reduction, improved patient compliance, and enhanced protection against pathogens.